中国中西医结合急救杂志2025，Vol.32Issue(3)：311-315,5.DOI:10.3969/j.issn.1008-9691.2025.03.010
海昆肾喜胶囊联合钠-葡萄糖协同转运蛋白抑制剂治疗终末期肾病的效果及机制分析
Effect and mechanism analysis of Haikun Shenxi capsule combined with sodium-glucose co-transporter 2 inhibitor on end-stage renal disease treatment
摘要
Abstract
Objective To explore the efficacy and mechanism of Haikun Shenxi capsules combined with sodium-glucose co-transporter 2 inhibitor(SGLT2i)in the treatment of end-stage renal disease(ESRD).Methods A prospective study was conducted,150 ESRD patients admitted to the department of nephrology of the First Affiliated Hospital of Baotou Medical College,Inner Mongolia University of Science and Technology from January 2024 to March 2025 were selected as the research subjects.The patients were divided into a control group,a treatment group,and a combined group using a random number table method,with 50 cases in each group.The control group was given compound Salvia Miltiorrhiza injection,the treatment group was given Haikun Shenxi capsules,and the combined group was given Haikun Shenxi capsules combined with an SGLT2i(Canagliflozin).All three groups were treated continuously for 4 weeks.The differences in clinical efficacy,renal function indicators[blood urea nitrogen(BUN),serum creatinine(SCr),endogenous creatinine clearance rate(Ccr),24-hour urine protein],renal fibrosis indicators[serum fibronectin(FN),serum hyaluronic acid(HA),serum laminin(LN),plasma typeⅢprocollagen(PC-Ⅲ)],inflammatory factor indicators[hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),vascular cell adhesion molecule-1(VCAM-1),monocyte chemoattractant protein-1(MCP-1)]before and after treatment,and adverse reactions were observed among the three groups.Results There were no statistically significant differences in renal function indicators,renal fibrosis indicators,and inflammatory factor indicators among the three groups before treatment;the total effective rate of treatment in the combined group was significantly higher than that in the control group and the treatment group[96.00%(48/50)vs.76.00%(38/50),84.00%(42/50),both P<0.05];after treatment,the levels of BUN,SCr,24-hour urine protein,HA,PC-Ⅲ,LN,hs-CRP,TNF-α,VCAM-1,and MCP-1 in the combined group were significantly lower than those in the control group and the treatment group[BUN(mmol/L):11.62±3.24 vs.18.56±4.37,15.34±4.24,SCr(μmol/L):152.38±20.61 vs.216.58±23.67,184.62±21.62,24-hour urine protein(mg):142.68±31.52 vs.246.29±46.34,195.64±34.28,HA(g/L):1.43±0.35 vs.2.61±0.32,2.16±0.34,PC-Ⅲ(μg/L):115.37±16.57 vs.135.81±18.65,127.64±17.48,LN(μg/L):125.67±24.19 vs.146.38±23.68,136.62±25.67,hs-CRP(mg/L):4.05±1.25 vs.5.16±1.42,4.62±1.38,TNF-α(ng/L):4.13±1.04 vs.5.06±1.18,4.62±1.08,VCAM-1(μg/L):0.81±0.23 vs.1.13±0.27,0.98±0.24,MCP-1(ng/L):72.19±10.62 vs.94.68±13.58,83.64±12.74,all P<0.05],the levels of Ccr and FN in the combined group were significantly higher than those in the control group and the treatment group[Ccr(mL/min):53.68±8.46 vs.34.34±6.27,41.68±7.25,FN(mg/L):154.69±21.67 vs.132.62±18.61,146.28±20.36,all P<0.05].There was no statistically significant difference in the incidence of adverse reactions among the three groups.Conclusion Haikun Shenxi capsules combined with SGLT2i have a more significant effect in the treatment of ESRD,which can improve renal function,delay renal fibrosis,reduce inflammatory response,and do not increase the incidence of adverse reactions.关键词
海昆肾喜胶囊/钠-葡萄糖协同转运蛋白2/终末期肾病/作用机制Key words
Haikun Shenxi capsule/Sodium-glucose co-transporter 2 inhibitor/End-stage renal disease/Action mechanism引用本文复制引用
张晟玮,崔少华..海昆肾喜胶囊联合钠-葡萄糖协同转运蛋白抑制剂治疗终末期肾病的效果及机制分析[J].中国中西医结合急救杂志,2025,32(3):311-315,5.基金项目
内蒙古医学科学院公立医院科研联合基金科技项目(2024GLLH0546) （2024GLLH0546）
包头医学院科学研究基金项目(BYJJ-ZRQM 202413) Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences(2024GLLH0546) （BYJJ-ZRQM 202413）
Baotou Medical College Scientific Research Fund Project(BYJJ-ZRQM 202413) （BYJJ-ZRQM 202413）
